dMMR Recurrent or Advanced
Endometrial Cancer

JEMPERLI—a PD-1 checkpoint inhibitor that may light the way for your patients whose disease has progressed on or after treatment with a platinum-containing regimen.1


JEMPERLI is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.

Icon: JEMPERLI (dostarlimab-gxly) Mechanism of Action

Learn how JEMPERLI
activates T cells.

Icon: JEMPERLI (dostarlimab-gxly) Safety

Learn about the safety profile
and tolerability of JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Dosing and Administration

Find out how to dose and
administer JEMPERLI.